Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.63 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9825847 | 1.00 | PPARA (0.67) | PPARAITGB3ITGA2BTACR1GPR34 | |
| SCHEMBL7307413 | 1.00 | PPARA (0.67) | PPARAITGB3ITGA2BTACR1GPR34 | |
| SCHEMBL5399121 | 0.93 | GPR34 (0.71) | PPARAITGB3ITGA2BGPR34 | |
| SCHEMBL11581034 | 0.92 | PPARA (0.58) | PPARAITGB3ITGA2BTACR1GPR34 | |
| SCHEMBL11581039 | 0.92 | PPARA (0.58) | PPARAITGB3ITGA2BTACR1GPR34 | |
| SCHEMBL2855187 | 0.92 | PPARA (0.61) | PPARAITGB3ITGA2BTACR1CTSL | |
| SCHEMBL2855186 | 0.92 | PPARA (0.61) | PPARAITGB3ITGA2BTACR1CTSL | |
| Hypochlorous Acid SCHEMBL7368156 | 0.92 | TACR1 (0.65) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL220648 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL219151 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767811-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-12-28 | — | — | US | disclosed |
| US-7057038-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1419125-A4 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | UNIV BRANDEIS (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | DENG LI (US) | 2005-01-27 | — | — | US | disclosed |
| US-6743914-B2 | USING TERTIARY AMINE CATALYST | BRANDEIS UNIVERSITY | 2004-06-01 | — | — | US | disclosed |
| EP-1419125-A1 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | Brandeis University (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1305270-B1 | KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | UNIV BRANDEIS (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030166963-A1 | Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-04 | — | — | US | disclosed |
| US-6562967-B2 | Drug screening; purity | BRANDEIS UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| US-5550131-A | ANTITHROMBOTIC AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| EP-0655055-A1 | TACHYKININ ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0643072-A1 | 2-Piperazinone compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994004494-A1 | TACHYKININ ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | PPARA 1133/4885ITGB3 1008/4885ITGA2B 2236/4885 |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | PPARA 1133/4885ITGB3 1008/4885ITGA2B 2236/4885 |
| US-20030166963-A1 | Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids | ADH5, ADH1C, TST | PPARA 1109/4885ITGB3 1859/4885ITGA2B 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.